

**Mouse Anti-IPO-38 (Proliferation Marker) [IPO38]: MC0068**

**Intended Use:** For Research Use Only

**Description:** Recognizes a protein of 14-16kDa, which is a novel nuclear antigen of proliferating cells. IPO-38 antigen is present in the nuclei of proliferating cells such as Hodgkin s disease and non-Hodgkin s lymphomas, different forms of leukemias, breast and colorectal carcinomas, and PHA-stimulated lymphocytes. It is not expressed in the cells of non-stimulated lymphocytes and granulocytes. IPO-38 may be a useful marker of cell proliferation during monitoring of tumor progression.

**Specifications**


Clone: IPO38  
Source: Mouse  
Isotype: IgM/k  
Reactivity: Human, mouse, rat  
Localization: Nucleus  
Formulation: Protein A/G purified antibody from bioreactor concentrate. Prepared in 10mM PBS with 0.2% BSA and < 0.09% sodium azide (NaN<sub>3</sub>)  
Storage: Store at 2°- 8°C. For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles  
Applications: IHC, Flow Cyt, ICC/IF, IP, WB  
Package:

Description	Catalog No.	Size
IPO-38 (Proliferation Marker) Concentrated	MC0068	1 ml

**IHC Procedure\***

Positive Control Tissue: Raji and PHA-stimulated (>12 hours) human or mouse lymphocytes. Breast and colorectal carcinomas  
Concentrated Dilution: 50-200  
Pretreatment: Citrate pH6.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
Incubation Time and Temp: 30-60 minutes @ RT  
Detection: Refer to the detection system manual

\* Result should be confirmed by an established diagnostic procedure.



FFPE human tonsil stained with anti-IPO-38 using DAB

**References**

1. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Molenaar RJ, et al. Cancer Res. Nov 15;75(22):4790-802, 2015.
2. Monoclonal antibody IPO-38 recognizes a novel nuclear antigen of proliferating cells. In Leucocyte Typing VI edited by Kishimoto T et al. Mikhalap SV, et al. Garland Publishing, Inc. New York & London. :609-610, 1997.
3. Experim. Oncol. Sidorenko SP, et al. 16:145-150, 1994.
4. Monoclonal antibodies of the IPO series in studying and diagnosing malignant lymphoproliferative diseases. Sidorenko SP, et al. Gematol Transfuziol 35:19-22, 1990.